Press Release
CGBIO Acquires the Lifting Thread Company ‘M.BASE’… Strengthening its Aesthetics Business Portfolio

▲ CGBIO Acquires the Lifting Thread Company ‘M.BASE’…
Strengthening its Aesthetics Business Portfolio

M.BASE is a lifting thread company with finished lifting thread product manufacturing facilities and development capabilities
Securing independent lifting thread manufacturing capacity and development know-how to generate synergy with existing aesthetic products

Bio-regenerative medicine company CGBIO (CEO Hyun Seung Yu) has acquired the lifting thread manufacturer and developer M.BASE (CEO Jin-ho Yu) to strengthen its aesthetics business portfolio.

On February 2, CGBIO announced that the company had concluded an agreement to acquire a 90% stake in M.BASE.

CGBIO has targeted and actively pursued the medical aesthetics business as its new business utilizing its biomaterial technology. The company’s aesthetic product portfolio includes hyaluronic acid (HA) filler Giselleligne, VOM filler (exported as AiLEENE), calcium filler Facetem, breast massager Beluna, and SVF fully-automated extractor Cellunit.

By acquiring M.BASE, CGBIO has secured independent lifting thread manufacturing capabilities and development know-how and strengthened its business portfolio related to aesthetics.

M.BASE is a lifting thread manufacturer and developer founded in 2017. The company is in possession of the GMP certification and medical device quality management system (ISO 13485) certification for its finished lifting thread manufacturing faculties. Furthermore, it has launched its own lifting thread brand ‘LUXX’ based on its independently developed technology, which is being exported to over 20 countries. Recently, the company was diversifying its pipelines through the development of medical sutures, etc.

Thread lifting improves the skin sagginess by inserting medical thread with bumps in the sagging skin and pulling and stabilizing the thread in the direction opposite to gravitational pull. It is much cheaper in cost compared to the full facelift performed through physical incisions. It offers the advantage of quicker procedure and recovery and less scarring, making it a popular form of procedure in the non-invasive cosmetic surgery market.

According to the British market survey and consulting company BrandEssence Market Research and Consulting Private Limited, the global lifting market size was USD 90.9 million in 2018 and USD 112.2 billion in 2020, and the market’s average annual growth rate was projected to be 7.4% with the market size reaching USD 177.69 million by 2026.

CGBIO CEO Hyun Seung Yu said, “Through this acquisition of M.BASE, CGBIO
has secured both manufacturing and development capabilities for lifting threads.” He added, “We will strive to accelerate our medical aesthetics businesses by generating optimal synergy with our other existing cosmetic surgery products.”